Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423483 | 0.72 | MAPT (0.68) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL24359598 | 0.72 | GAA (0.52) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL5960375 | 0.70 | GAA (0.38) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL6752324 | 0.70 | CCR1 (0.54) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL5027456 | 0.69 | MEN1 (0.63) | KDM4EMAPTGAAALDH1A1POLB | |
| SCHEMBL533381 | 0.69 | GAA (0.61) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL4160754 | 0.68 | KDM4E (0.54) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL10211630 | 0.66 | KDM4E (0.46) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL13108779 | 0.66 | KDM4E (0.46) | KDM4EMAPTGAAALDH1A1RECQL | |
| SCHEMBL3845266 | 0.66 | RECQL (0.42) | KDM4EMAPTGAAALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | claimed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | claimed |
| EP-2155724-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | claimed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | claimed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | claimed |
| WO-2008124524-A2 | ARYL SULFONAMIDE COMPOUNDS AS MODULATORS OF THE CCK2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-16 | — | — | WO | claimed |
| WO-2008116833-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | claimed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| WO-2004020402-A1 | SULPHONYLAMINO DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-03-11 | — | — | WO | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| WO-2001070677-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | KDM4E 3376/4885MAPT 3696/4885GAA 3513/4885 |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | KDM4E 1795/4885MAPT 4220/4885GAA 1688/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | KDM4E 2316/4885MAPT 4295/4885GAA 3237/4885 |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR4, HTR3C | KDM4E 3620/4885MAPT 4616/4885GAA 2537/4885 |
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | KDM4E 4712/4885MAPT 3353/4885GAA 399/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | KDM4E 126/4885MAPT 1836/4885GAA 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.